Stromal p16 expression is significantly increased in endometrial carcinoma

Gun Yoon, Chang Won Koh, Nara Yoon, Ji Ye Kim, Hyun Soo Kim

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

p16 is a negative regulator of cell proliferation and is considered a tumor suppressor protein. Alterations in p16 protein expression are associated with tumor development and progression. However, the p16 expression status in the peritumoral stroma has not been investigated in the endometrium. Therefore, we evaluated stromal p16 expression in different types of endometrial lesions using immunohistochemistry. Differences in the p16 expression status according to the degree of malignancy and histological type were analyzed. This study included 62, 26, and 36 cases of benign, precancerous, and malignant endometrial lesions, respectively. Most benign lesions showed negative or weak expression, whereas precancerous lesions showed a variable degree of staining proportion and intensity. Atypical hyperplasia/endometrial intraepithelial neoplasia (AH/EIN) and serous endometrial intraepithelial carcinoma (SEIC) had significantly higher stromal p16 expression levels than benign lesions. Endometrioid carcinoma (EC), serous carcinoma (SC), and carcinosarcoma showed significantly elevated stromal p16 expression levels compared with benign and precancerous lesions. In addition, there were significant differences in stromal p16 expression between AH/EIN and SEIC and between EC and SC. In contrast, differences in stromal p16 expression among nonpathological endometrium, atrophic endometrium, endometrial polyp, and hyperplasia without atypia were not statistically significant. Our observations suggest that stromal p16 expression is involved in the development and progression of endometrial carcinoma, and raise the possibility that p16 overexpression in the peritumoral stroma is associated with aggressive oncogenic behavior of endometrial SC.

Original languageEnglish
Pages (from-to)4826-4836
Number of pages11
JournalOncotarget
Volume8
Issue number3
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Endometrial Neoplasms
Endometrial Hyperplasia
Endometrium
Endometrioid Carcinoma
Carcinoma in Situ
Neoplasms
Carcinoma
Tumor Suppressor Proteins
Carcinosarcoma
Polyps
Immunohistochemistry
Cell Proliferation
Staining and Labeling
Proteins

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Yoon, Gun ; Koh, Chang Won ; Yoon, Nara ; Kim, Ji Ye ; Kim, Hyun Soo. / Stromal p16 expression is significantly increased in endometrial carcinoma. In: Oncotarget. 2017 ; Vol. 8, No. 3. pp. 4826-4836.
@article{4a2b14e79591453c896fa228b857e61e,
title = "Stromal p16 expression is significantly increased in endometrial carcinoma",
abstract = "p16 is a negative regulator of cell proliferation and is considered a tumor suppressor protein. Alterations in p16 protein expression are associated with tumor development and progression. However, the p16 expression status in the peritumoral stroma has not been investigated in the endometrium. Therefore, we evaluated stromal p16 expression in different types of endometrial lesions using immunohistochemistry. Differences in the p16 expression status according to the degree of malignancy and histological type were analyzed. This study included 62, 26, and 36 cases of benign, precancerous, and malignant endometrial lesions, respectively. Most benign lesions showed negative or weak expression, whereas precancerous lesions showed a variable degree of staining proportion and intensity. Atypical hyperplasia/endometrial intraepithelial neoplasia (AH/EIN) and serous endometrial intraepithelial carcinoma (SEIC) had significantly higher stromal p16 expression levels than benign lesions. Endometrioid carcinoma (EC), serous carcinoma (SC), and carcinosarcoma showed significantly elevated stromal p16 expression levels compared with benign and precancerous lesions. In addition, there were significant differences in stromal p16 expression between AH/EIN and SEIC and between EC and SC. In contrast, differences in stromal p16 expression among nonpathological endometrium, atrophic endometrium, endometrial polyp, and hyperplasia without atypia were not statistically significant. Our observations suggest that stromal p16 expression is involved in the development and progression of endometrial carcinoma, and raise the possibility that p16 overexpression in the peritumoral stroma is associated with aggressive oncogenic behavior of endometrial SC.",
author = "Gun Yoon and Koh, {Chang Won} and Nara Yoon and Kim, {Ji Ye} and Kim, {Hyun Soo}",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.13594",
language = "English",
volume = "8",
pages = "4826--4836",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "3",

}

Stromal p16 expression is significantly increased in endometrial carcinoma. / Yoon, Gun; Koh, Chang Won; Yoon, Nara; Kim, Ji Ye; Kim, Hyun Soo.

In: Oncotarget, Vol. 8, No. 3, 01.01.2017, p. 4826-4836.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Stromal p16 expression is significantly increased in endometrial carcinoma

AU - Yoon, Gun

AU - Koh, Chang Won

AU - Yoon, Nara

AU - Kim, Ji Ye

AU - Kim, Hyun Soo

PY - 2017/1/1

Y1 - 2017/1/1

N2 - p16 is a negative regulator of cell proliferation and is considered a tumor suppressor protein. Alterations in p16 protein expression are associated with tumor development and progression. However, the p16 expression status in the peritumoral stroma has not been investigated in the endometrium. Therefore, we evaluated stromal p16 expression in different types of endometrial lesions using immunohistochemistry. Differences in the p16 expression status according to the degree of malignancy and histological type were analyzed. This study included 62, 26, and 36 cases of benign, precancerous, and malignant endometrial lesions, respectively. Most benign lesions showed negative or weak expression, whereas precancerous lesions showed a variable degree of staining proportion and intensity. Atypical hyperplasia/endometrial intraepithelial neoplasia (AH/EIN) and serous endometrial intraepithelial carcinoma (SEIC) had significantly higher stromal p16 expression levels than benign lesions. Endometrioid carcinoma (EC), serous carcinoma (SC), and carcinosarcoma showed significantly elevated stromal p16 expression levels compared with benign and precancerous lesions. In addition, there were significant differences in stromal p16 expression between AH/EIN and SEIC and between EC and SC. In contrast, differences in stromal p16 expression among nonpathological endometrium, atrophic endometrium, endometrial polyp, and hyperplasia without atypia were not statistically significant. Our observations suggest that stromal p16 expression is involved in the development and progression of endometrial carcinoma, and raise the possibility that p16 overexpression in the peritumoral stroma is associated with aggressive oncogenic behavior of endometrial SC.

AB - p16 is a negative regulator of cell proliferation and is considered a tumor suppressor protein. Alterations in p16 protein expression are associated with tumor development and progression. However, the p16 expression status in the peritumoral stroma has not been investigated in the endometrium. Therefore, we evaluated stromal p16 expression in different types of endometrial lesions using immunohistochemistry. Differences in the p16 expression status according to the degree of malignancy and histological type were analyzed. This study included 62, 26, and 36 cases of benign, precancerous, and malignant endometrial lesions, respectively. Most benign lesions showed negative or weak expression, whereas precancerous lesions showed a variable degree of staining proportion and intensity. Atypical hyperplasia/endometrial intraepithelial neoplasia (AH/EIN) and serous endometrial intraepithelial carcinoma (SEIC) had significantly higher stromal p16 expression levels than benign lesions. Endometrioid carcinoma (EC), serous carcinoma (SC), and carcinosarcoma showed significantly elevated stromal p16 expression levels compared with benign and precancerous lesions. In addition, there were significant differences in stromal p16 expression between AH/EIN and SEIC and between EC and SC. In contrast, differences in stromal p16 expression among nonpathological endometrium, atrophic endometrium, endometrial polyp, and hyperplasia without atypia were not statistically significant. Our observations suggest that stromal p16 expression is involved in the development and progression of endometrial carcinoma, and raise the possibility that p16 overexpression in the peritumoral stroma is associated with aggressive oncogenic behavior of endometrial SC.

UR - http://www.scopus.com/inward/record.url?scp=85011995393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011995393&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.13594

DO - 10.18632/oncotarget.13594

M3 - Article

AN - SCOPUS:85011995393

VL - 8

SP - 4826

EP - 4836

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 3

ER -